Century Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Century Therapeutics, Inc. (IPSC) had Debt Securities, Available-for-sale, Amortized Cost of $238.79 million as of 2023-06-30, per its 10-Q filed 2023-08-09.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2023-08-09
- 2023-06-30: Debt Securities, Available-for-sale, Amortized Cost $238.79M.
- 2023-03-31: Debt Securities, Available-for-sale, Amortized Cost $249.14M.
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost $285.47M.
- 2022-09-30: Debt Securities, Available-for-sale, Amortized Cost $287.46M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2023-06-30 | $238.79M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $249.14M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $285.47M 10-Q · filed 2023-08-09 |
| 2022-09-30 | $287.46M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $319.94M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $342.92M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $302.95M 10-K · filed 2023-03-16 |
| 2021-09-30 | $299.07M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $167.75M 10-Q · filed 2021-08-12 |
| 2020-12-31 | $49.59M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |